Literature DB >> 17650455

Antibodies against the CUB1-2 domains of ADAMTS13 in a patient with benign monoclonal gammopathy: no causal relationship.

Niels P Riksen1, Brenda M Luken, Ina S Klasen, Jan Voorberg, Niels Crama, Marcel van Deuren.   

Abstract

We present a patient with a history of benign monoclonal gammopathy, who developed thrombotic thrombocytopenic purpura (TTP), initially presenting as bilateral serous retinal detachment. Plasma of the patient contained high titers of anti ADAMTS13 antibodies that were directed towards the disintegrin/TSR1/cysteine-rich/spacer and CUB1-2 domains. ADAMTS13 activity was undetectable. Total IgG purified from plasma of the patient partially inhibited ADAMTS13 activity. In contrast, the isolated M-protein did neither bind to, nor inhibit activity of ADAMTS13. We conclude that in this patient the monoclonal gammopathy and TTP co-existed as distinct pathological entities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17650455     DOI: 10.3324/haematol.11475

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  4 in total

1.  Cysteine residues in CUB-1 domain are critical for ADAMTS13 secretion and stability.

Authors:  Zhou Zhou; Hui-Chun Yeh; Hua Jing; Christina Wang; Zhenyin Tao; Huiwan Choi; Khatira Aboulfatova; Renhai Li; Jing-Fei Dong
Journal:  Thromb Haemost       Date:  2010-09-30       Impact factor: 5.249

2.  Effects of naturally occurring mutations in CUB-1 domain on synthesis, stability, and activity of ADAMTS-13.

Authors:  Zhou Zhou; Hua Jing; Zhenyin Tao; Huiwan Choi; Khatira Aboulfatova; Joel Moake; Renhao Li; Jing-Fei Dong
Journal:  Thromb Res       Date:  2008-11-21       Impact factor: 3.944

3.  IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: a case report.

Authors:  Xin-Yao Wu; Yu-Feng Yin; Jia-Lin Teng; Li-Wei Zhang; Cheng-de Yang
Journal:  BMC Immunol       Date:  2017-06-23       Impact factor: 3.615

4.  Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report.

Authors:  Clarissa A Cassol; Michael P A Williams; Tiffany N Caza; Sophia Rodriguez
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.